Compare F.N.B. Corporation Common Stock (FNB) vs SELLAS Life Sciences Group Inc. Common Stock (SLS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F.N.B. Corporation Common Stock vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? F.N.B. Corporation Common Stock trades at $16.96 (market cap $6.03B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.76 (market cap $2.40B). The key difference: F.N.B. Corporation Common Stock is far larger — about 2.5× SELLAS Life Sciences Group Inc. Common Stock's market cap, and F.N.B. Corporation Common Stock pays a 3.07% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold F.N.B. Corporation Common Stock for 0 Days and SELLAS Life Sciences Group Inc. Common Stock for 0 Days on average.
| FNB | SLS | |
|---|---|---|
Market Cap | $6.03B | $2.40B |
Volume | 7,117,178 | 4,725,416 |
Sector | Financials | Health |
52-Week High | $19.49 | $15.46 |
52-Week Low | $14.65 | $1.39 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $10.52B | $2.26B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FNB trades at $17.05, down 0.76% on the day, with a neutral technical signal. The stock shows solid fundamentals with a P/E of 10.15 and P/B of 0.89, indicating potential undervaluation. Recent earnings have been mixed, with Q2 2026 beating estimates but Q1 missing. Revenue remains stable at $1.77 billion for 2025, with a strong net income margin of 33.04%. Analyst sentiment is positive, with 13 buy ratings and a consensus price target of $20.80.
The outlook for FNB is cautiously optimistic, supported by strong profitability and a favorable analyst consensus. Key opportunities include potential upside to the price target and consistent dividend payments. Risks involve earnings volatility, as seen in recent quarters, and competitive pressures in the banking sector. Investors should weigh the attractive valuation against execution risks and market conditions.
SELLAS Life Sciences (SLS) trades at $12.41, up 4.02% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported no revenue in 2025, with a net loss of $26.86 million, negative ROE and ROA, and a high P/B ratio of 18.2. Recent news includes a law firm investigation into investor claims and positive preclinical data for SLS009 in pancreatic cancer models presented at the AACR conference.
The outlook hinges on upcoming clinical trial results, particularly the Phase 3 REGAL trial for GPS in AML, with topline data expected in Q4 2026. While analyst consensus is unanimously bullish, significant risks include the binary nature of trial outcomes, ongoing legal scrutiny, and persistent negative profitability metrics. The stock's recent surge of ~300% year-to-date reflects high investor optimism but also heightened volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About F.N.B. Corporation Common Stock
F.N.B. Corporation is a diversified financial services holding company headquartered in Pittsburgh, Pennsylvania, operating through its lead subsidiary, First National Bank of Pennsylvania. It provides commercial banking, consumer banking, wealth management, and insurance through more than 350 banking offices across seven states and Washington, D.C.
Read more on FNB →About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →
